185 related articles for article (PubMed ID: 36529353)
1. Mitochondrial-targeted nanoparticles: Delivery and therapeutic agents in cancer.
Ganji C; Muppala V; Khan M; Nagaraju GP; Farran B
Drug Discov Today; 2023 Mar; 28(3):103469. PubMed ID: 36529353
[TBL] [Abstract][Full Text] [Related]
2. Mitochondria and Mitochondrial ROS in Cancer: Novel Targets for Anticancer Therapy.
Yang Y; Karakhanova S; Hartwig W; D'Haese JG; Philippov PP; Werner J; Bazhin AV
J Cell Physiol; 2016 Dec; 231(12):2570-81. PubMed ID: 26895995
[TBL] [Abstract][Full Text] [Related]
3. Mitocans Revisited: Mitochondrial Targeting as Efficient Anti-Cancer Therapy.
Dong L; Gopalan V; Holland O; Neuzil J
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33114695
[TBL] [Abstract][Full Text] [Related]
4. The causes of cancer revisited: "mitochondrial malignancy" and ROS-induced oncogenic transformation - why mitochondria are targets for cancer therapy.
Ralph SJ; Rodríguez-Enríquez S; Neuzil J; Saavedra E; Moreno-Sánchez R
Mol Aspects Med; 2010 Apr; 31(2):145-70. PubMed ID: 20206201
[TBL] [Abstract][Full Text] [Related]
5. Mitochondria-targeted drug delivery in cancers.
Cho H; Cho YY; Shim MS; Lee JY; Lee HS; Kang HC
Biochim Biophys Acta Mol Basis Dis; 2020 Aug; 1866(8):165808. PubMed ID: 32333953
[TBL] [Abstract][Full Text] [Related]
6. Dequalinium-based functional nanosomes show increased mitochondria targeting and anticancer effect.
Bae Y; Jung MK; Lee S; Song SJ; Mun JY; Green ES; Han J; Ko KS; Choi JS
Eur J Pharm Biopharm; 2018 Mar; 124():104-115. PubMed ID: 29305141
[TBL] [Abstract][Full Text] [Related]
7. Stress-related mitochondrial components and mitochondrial genome as targets of anticancer therapy.
Giannattasio S; Guaragnella N; Arbini AA; Moro L
Chem Biol Drug Des; 2013 Jan; 81(1):102-12. PubMed ID: 23253132
[TBL] [Abstract][Full Text] [Related]
8. Hierarchical targeted hepatocyte mitochondrial multifunctional chitosan nanoparticles for anticancer drug delivery.
Chen Z; Zhang L; Song Y; He J; Wu L; Zhao C; Xiao Y; Li W; Cai B; Cheng H; Li W
Biomaterials; 2015 Jun; 52():240-50. PubMed ID: 25818430
[TBL] [Abstract][Full Text] [Related]
9. Small mitochondria-targeting molecules as anti-cancer agents.
Wang F; Ogasawara MA; Huang P
Mol Aspects Med; 2010 Feb; 31(1):75-92. PubMed ID: 19995573
[TBL] [Abstract][Full Text] [Related]
10. The role of compartmentalized signaling pathways in the control of mitochondrial activities in cancer cells.
Rinaldi L; Delle Donne R; Borzacchiello D; Insabato L; Feliciello A
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):293-302. PubMed ID: 29673970
[TBL] [Abstract][Full Text] [Related]
11. ROS-responsive nano-drug delivery system combining mitochondria-targeting ceria nanoparticles with atorvastatin for acute kidney injury.
Yu H; Jin F; Liu D; Shu G; Wang X; Qi J; Sun M; Yang P; Jiang S; Ying X; Du Y
Theranostics; 2020; 10(5):2342-2357. PubMed ID: 32104507
[TBL] [Abstract][Full Text] [Related]
12. Mitochondria Deregulations in Cancer Offer Several Potential Targets of Therapeutic Interventions.
Musicco C; Signorile A; Pesce V; Loguercio Polosa P; Cormio A
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445598
[TBL] [Abstract][Full Text] [Related]
13. Friend or foe? Mitochondria as a pharmacological target in cancer treatment.
Dickerson T; Jauregui CE; Teng Y
Future Med Chem; 2017 Dec; 9(18):2197-2210. PubMed ID: 29182013
[TBL] [Abstract][Full Text] [Related]
14. Mitochondria-targeted nanoplatforms for enhanced photodynamic therapy against hypoxia tumor.
Wen J; Luo Y; Gao H; Zhang L; Wang X; Huang J; Shang T; Zhou D; Wang D; Wang Z; Li P; Wang Z
J Nanobiotechnology; 2021 Dec; 19(1):440. PubMed ID: 34930284
[TBL] [Abstract][Full Text] [Related]
15. Targeting mitochondria in fighting cancer.
Gogvadze V
Curr Pharm Des; 2011 Dec; 17(36):4034-46. PubMed ID: 22188453
[TBL] [Abstract][Full Text] [Related]
16. To betray or to fight? The dual identity of the mitochondria in cancer.
Zhang X; Su Q; Zhou J; Yang Z; Liu Z; Ji L; Gao H; Jiang G
Future Oncol; 2021 Feb; 17(6):723-743. PubMed ID: 33459048
[TBL] [Abstract][Full Text] [Related]
17. A Novel Self-Assembled Mitochondria-Targeting Protein Nanoparticle Acting as Theranostic Platform for Cancer.
Zhu XJ; Li RF; Xu L; Yin H; Chen L; Yuan Y; Zhong W; Lin J
Small; 2019 Jan; 15(2):e1803428. PubMed ID: 30450734
[TBL] [Abstract][Full Text] [Related]
18. Interplay Between Mitochondrial Peroxiredoxins and ROS in Cancer Development and Progression.
Ismail T; Kim Y; Lee H; Lee DS; Lee HS
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31500275
[TBL] [Abstract][Full Text] [Related]
19. Mitochondrial drug delivery systems for macromolecule and their therapeutic application to mitochondrial diseases.
Yamada Y; Harashima H
Adv Drug Deliv Rev; 2008; 60(13-14):1439-62. PubMed ID: 18655816
[TBL] [Abstract][Full Text] [Related]
20. A pH-Activatable nanoparticle for dual-stage precisely mitochondria-targeted photodynamic anticancer therapy.
Qi T; Chen B; Wang Z; Du H; Liu D; Yin Q; Liu B; Zhang Q; Wang Y
Biomaterials; 2019 Aug; 213():119219. PubMed ID: 31132647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
